Curcumin: Towards molecularly targeted chemoprevention of cancer

Ulrich Pfeffer , Adriana Amaro , Beatrice Bachmeier , Giovanna Angelini
{"title":"Curcumin: Towards molecularly targeted chemoprevention of cancer","authors":"Ulrich Pfeffer ,&nbsp;Adriana Amaro ,&nbsp;Beatrice Bachmeier ,&nbsp;Giovanna Angelini","doi":"10.1016/j.nhtm.2014.11.018","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>Everybody is at risk for cancer yet environmental factors<span><span>, lifestyle and diet as well as genetic factors<span><span> influence the individual cancer risk. Targeted or personalized cancer prevention is based on the knowledge of the molecular characteristics of the tumor to be prevented, the molecular mechanisms of action of the compounds to be used and the genetic make-up of the person who opts for prevention medicine<span>. Genetic factors are to a certain extent specific for cancer types or even subtypes as it has been shown for breast cancer. The growing knowledge of such genotype cancer risk associations will allow for the definition of personalized prevention strategies. Prevention in </span></span>intermediate risk populations<span> requires non-toxic, well tolerated and cheap compounds. The main activity of the polyphenol Curcumin is the inhibition of </span></span></span>nuclear factor kappa B<span> (NFkB) activation. NFkB is involved in many cancers where it acts through the generation of chronic inflammation<span><span> that can be contrasted by the anti-inflammatory activity of Curcumin. Curcumin mediated inhibition of NFkB leads to the interruption of a pro-metastatic positive feedback loop where NFkB induces the expression of inflammatory cytokines which in turn promote NFkB activation and the transcription of NFkB regulated pro-metastatic factors such as COX2, </span>SPARC<span>, ALDH3A1 and EFEMP1. By interrupting this loop Curcumin significantly reduces the formation of metastases in murine breast and </span></span></span></span></span>prostate cancer models. </span>Clinical trials<span> for primary prevention must rely on a risk based selection of participants and well characterized response markers. Targeted cancer prevention can be applied as primary prevention, after diagnosis in low risk situations where watchful waiting could be integrated by prevention drugs and after adjuvant therapy to contrast the remaining risk of relapse. Adequately targeted, cancer prevention approaches are expected to outperform the effects of current cancer therapy in terms of overall survival.</span></p></div>","PeriodicalId":90660,"journal":{"name":"New horizons in translational medicine","volume":"2 2","pages":"Page 60"},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.nhtm.2014.11.018","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"New horizons in translational medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2307502314000356","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Everybody is at risk for cancer yet environmental factors, lifestyle and diet as well as genetic factors influence the individual cancer risk. Targeted or personalized cancer prevention is based on the knowledge of the molecular characteristics of the tumor to be prevented, the molecular mechanisms of action of the compounds to be used and the genetic make-up of the person who opts for prevention medicine. Genetic factors are to a certain extent specific for cancer types or even subtypes as it has been shown for breast cancer. The growing knowledge of such genotype cancer risk associations will allow for the definition of personalized prevention strategies. Prevention in intermediate risk populations requires non-toxic, well tolerated and cheap compounds. The main activity of the polyphenol Curcumin is the inhibition of nuclear factor kappa B (NFkB) activation. NFkB is involved in many cancers where it acts through the generation of chronic inflammation that can be contrasted by the anti-inflammatory activity of Curcumin. Curcumin mediated inhibition of NFkB leads to the interruption of a pro-metastatic positive feedback loop where NFkB induces the expression of inflammatory cytokines which in turn promote NFkB activation and the transcription of NFkB regulated pro-metastatic factors such as COX2, SPARC, ALDH3A1 and EFEMP1. By interrupting this loop Curcumin significantly reduces the formation of metastases in murine breast and prostate cancer models. Clinical trials for primary prevention must rely on a risk based selection of participants and well characterized response markers. Targeted cancer prevention can be applied as primary prevention, after diagnosis in low risk situations where watchful waiting could be integrated by prevention drugs and after adjuvant therapy to contrast the remaining risk of relapse. Adequately targeted, cancer prevention approaches are expected to outperform the effects of current cancer therapy in terms of overall survival.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
姜黄素:对癌症的分子靶向化学预防
每个人都有患癌症的风险,但环境因素、生活方式、饮食以及遗传因素都会影响个人患癌症的风险。有针对性或个性化的癌症预防是基于对要预防的肿瘤的分子特征、要使用的化合物的分子作用机制和选择预防药物的人的基因组成的了解。遗传因素在某种程度上是特定于癌症类型甚至亚型的正如乳腺癌所显示的那样。对这种基因型癌症风险关联的日益了解将有助于制定个性化的预防策略。在中等风险人群中进行预防需要无毒、耐受性良好和廉价的化合物。多酚姜黄素的主要作用是抑制核因子κ B (NFkB)的活化。NFkB与许多癌症有关,它通过产生慢性炎症而起作用,这与姜黄素的抗炎活性形成对比。姜黄素介导的NFkB抑制导致促转移正反馈回路中断,其中NFkB诱导炎症细胞因子的表达,进而促进NFkB的激活和NFkB调控的促转移因子如COX2、SPARC、ALDH3A1和EFEMP1的转录。通过阻断这个循环,姜黄素显著减少小鼠乳腺癌和前列腺癌模型中转移灶的形成。初级预防的临床试验必须依赖于基于风险的参与者选择和特征明确的反应标志物。靶向癌症预防可作为一级预防,在低风险情况下诊断后可结合预防药物观察等待,辅助治疗后对比剩余复发风险。充分靶向,癌症预防方法有望在总体生存方面优于当前癌症治疗的效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Contents Editorial Board Improving disease diagnosis by a new hybrid model Pros, cons and future of antibiotics Abstracts: 5th Annual Congress of the European Society for Translational Medicine (EUSTM-2017), 20-22 October 2017, Berlin, Germany
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1